Advertisement
HRMY vs KROS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRMY is a Hold and KROS is a Hold.
HRMY in downward trend: 10-day moving average moved below 50-day moving average on October 08, 2026
The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 32 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
HRMY moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for HRMY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HRMY's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.930) is normal, around the industry mean (3.498). P/E Ratio (10.578) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KROS's Indicator enters downward trend
The Aroon Indicator for KROS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In 166 of the 196 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 68 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 31 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 225 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.498). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRMY | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 46 | 95 | |
PRICE GROWTH RATING 1..100 | 61 | 78 | |
P/E GROWTH RATING 1..100 | 38 | 98 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (26) in the null industry is somewhat better than the same rating for HRMY (81). This means that KROS’s stock grew somewhat faster than HRMY’s over the last 12 months.
KROS's Profit vs Risk Rating (100) in the null industry is in the same range as HRMY (100). This means that KROS’s stock grew similarly to HRMY’s over the last 12 months.
HRMY's SMR Rating (46) in the null industry is somewhat better than the same rating for KROS (95). This means that HRMY’s stock grew somewhat faster than KROS’s over the last 12 months.
HRMY's Price Growth Rating (61) in the null industry is in the same range as KROS (78). This means that HRMY’s stock grew similarly to KROS’s over the last 12 months.
HRMY's P/E Growth Rating (38) in the null industry is somewhat better than the same rating for KROS (98). This means that HRMY’s stock grew somewhat faster than KROS’s over the last 12 months.
| HRMY | KROS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 76% |
| Advances ODDS (%) | 3 days ago 73% | 15 days ago 77% |
| Declines ODDS (%) | 7 days ago 74% | 3 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HRMY’s FA Score shows that 0 FA rating(s) are green while KROS’s FA Score has 1 green FA rating(s).
- HRMY’s FA Score: 0 green, 5 red.
- KROS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HRMY’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 4 bullish TA indicator(s).
- HRMY’s TA Score: 4 bullish, 6 bearish.
- KROS’s TA Score: 4 bullish, 6 bearish.
Price Growth
HRMY (@Biotechnology) experienced а -9.37% price change this week, while KROS (@Biotechnology) price change was -13.85% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
HRMY is expected to report earnings on Mar 02, 2027.
KROS is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HRMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNDX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNDX could also see price increases.
| Ticker / NAME | Correlation To HRMY | 1D Price Change % | ||
|---|---|---|---|---|
| HRMY | 100% | -0.68% | ||
| SNDX - HRMY | 36% Loosely correlated | -0.63% | ||
| KURA - HRMY | 35% Loosely correlated | N/A | ||
| EXEL - HRMY | 34% Loosely correlated | -1.62% | ||
| KROS - HRMY | 34% Loosely correlated | +1.74% | ||
| RXRX - HRMY | 33% Loosely correlated | -6.70% | ||
More | ||||
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +1.74% | ||
| SANA - KROS | 50% Loosely correlated | -1.42% | ||
| IMNM - KROS | 46% Loosely correlated | -3.67% | ||
| ARVN - KROS | 45% Loosely correlated | +2.37% | ||
| LXEO - KROS | 45% Loosely correlated | -2.55% | ||
| MGTX - KROS | 45% Loosely correlated | +1.37% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BGR | 16.80 | 0.06 | +0.36% |
| Blackrock Energy and Resources Trust | |||
| FELV | 43.55 | 0.08 | +0.18% |
| Fidelity Enhanced Large Cap Value ETF (FELV) | |||
| SPBC | 48.59 | -0.34 | -0.70% |
| Simplify US Equity PLUS Bitcoin Strategy ETF (SPBC) | |||
| VTN | 10.14 | -0.16 | -1.55% |
| Invesco Trust for Investment Grade New York Municipals | |||
| BABU | 7.73 | -0.40 | -4.88% |
| Direxion Daily BABA Bull 2X ETF (BABU) | |||